Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
68 hedge funds and large institutions have $140M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 12 closing their positions.
257% more call options, than puts
Call options by funds: $200K | Put options by funds: $56K
141% more capital invested
Capital invested by funds: $58.1M → $140M (+$81.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
21% more funds holding
Funds holding: 56 → 68 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.76M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$7.19M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$6.85M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.85M |
| 2 |
JP Morgan Chase
New York
|
-$400K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$233K |
| 4 |
E
Ergoteles
New York
|
-$140K |
| 5 |
Renaissance Technologies
New York
|
-$122K |
PSTX Hedge Fund Activity: Q3 2022 in Review
68 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2022, worth a combined $140M — up 141% from $58.1M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PSTX positions and 12 closed out — a net gain of 12 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was Millennium Management, cutting an estimated $2.85M.
- 68 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2022, up from 56 in Q2 2022.
- Funds reported $140M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2022, up 141% quarter-over-quarter.
- 24 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of +12 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2022 was Fidelity Investments, an estimated $10.4M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $2.85M sold.
Based on aggregated 13F filings for Q3 2022.